Carcinoma clinical trials

Explore recruiting carcinoma clinical trials.

Recruiting carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Avelumab (MSB0010718C) Clinical Studies

Italy, Bulgaria, Poland, Romania, France, Spain +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937)

Germany, Belgium, Italy, France, Sweden, Hungary +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma

Spain, Netherlands, Finland, Romania, France, Hungary +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase 2 trial of neoadjuVAnt muLti-agENT chemotherapy or patritumab deruxtecan (HER3-DXd; U3-1402) with or without endocrINE therapy for high-risk HR+/HER2- breast cancer – VALENTINE trial

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

IFCT-2103 DIAL De-escalation Immunotherapy mAintenance duration trial for stage IV Lung cancer patients with disease control after chemo-immunotherapy induction A phase II-III randomized trial evaluating maintenance pembrolizumab (± pemetrexed) until progression versus observation (± pemetrexed) after 6 months of platinum-based doublet chemotherapy plus pembrolizumab induction treatment in patients with stage IV Non-Small Cell Lung Cancer (NSCLC)

France

Phase II and Phase III (Integrated) EU CTIS Study details

INtra-operative evaluation of a novel FLUorescENt C-mEt tracer in penile and tongue cancer - INFLUENCE

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

Carcinoma trials by city

Carcinoma in Toronto Carcinoma in Vancouver Carcinoma in Montreal Carcinoma in Calgary Carcinoma in Edmonton Carcinoma in Ottawa Carcinoma in Winnipeg Carcinoma in Quebec City Carcinoma in Hamilton Carcinoma in Kitchener Carcinoma in London Carcinoma in Halifax Carcinoma in New York Carcinoma in Los Angeles Carcinoma in Chicago Carcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease